Mirada Medical Showcases Latest Imaging Solutions at ECCO, Efficiently Unites Cancer Treatment Team

OXFORD, UK and PHILADELPHIA, PA--(Marketwire - September 20, 2011) - Mirada Medical will be introducing their Casemeeting software at the European Cancer Organization (ECCO) conference being held September 24-25 in Stockholm, Sweden. The conference brings together the European Society for Medical Oncology (ESMO) and the European Society for Radiation Oncology (ESTRO) to form the European Multidisciplinary Cancer Congress.

Casemeeting is the company’s latest innovative software-based solution for multidisciplinary cancer care. When integrated with Mirada’s suite of products for diagnostic oncology, medical oncology and radiation oncology, Casemeeting promotes improved collaboration by supporting seamless and efficient communication of detailed information across the entire multidisciplinary cancer treatment team. Casemeeting uniquely allows collaborators to efficiently store, organize and present image based patient information at multidisciplinary team meetings.

“The focus on multidisciplinary oncology care at ECCO is an ideal setting for demonstrating Casemeeting’’, stated Hugh Bettesworth, Mirada Medical’s CEO. ''Mirada has become well respected for its powerful technology solutions for individual disciplines. Now, Casemeeting fulfills our commitment to allow the individual disciplines to collaborate with one another through the effective communication of detailed and relevant case knowledge, particularly via the multidisciplinary meeting.”

Mirada Medical will demonstrate its entire product suite at ECCO.

For radiation therapy planning, the company will highlight workflows which automate complex tasks such as: image registration, dose summation, atlas-based contouring and automatic deformable transfer of contours from previous plan to the current plan. Mirada’s radiation oncology products also support the full integration of PET and MRI into the planning process, as well as workflows for adaptive radiation therapy planning.

For the medical oncologist, the company will show advanced multi-modal and multi-timepoint treatment response assessment where the clinical user is able to generate a quantified response report using all of the available patient images regardless of the time span over which the treatment has been carried out.

For diagnostic oncology, Mirada will demonstrate the latest version of its XD3 multi-modality reading application. XD3 may be used to analyse CT images together with PET, MR or SPECT in a single reading workflow. It also includes enhanced support for advanced tri-modal fusion of MRI with PET-CT. The software supports standardised treatment response protocols such as RECIST and PERCIST making XD3 ideally suited for clinical trials.

About Mirada Medical
Mirada Medical is an internationally recognised brand in advanced medical imaging. The company develops high value clinical software applications, which are used across diagnostic radiology, nuclear medicine, radiation oncology, tumor board and elsewhere.

Mirada specializes in simplifying technically complex image quantification, allowing clinicians to more confidently diagnose disease, assess response to treatment and plan radiation therapy or surgical intervention.

Mirada was originally spun out of the University of Oxford. The company’s technologies are, to this day, developed by a team of dedicated engineers and world-renowned scientists working out of Oxford, England.

Mirada’s products have been designed to ease the deployment of these powerful technologies into any hospital or imaging center workflow. Mirada’s applications can be delivered using thin client or cloud based architectures, or licensed on a floating or per workstation basis. Most recently, Mirada has focused on the development of disease specific solutions for use across departments working with patients to fight cancer. In particular, Mirada’s powerful image registration technologies have been tuned to the needs of radiation oncology, and quantification technologies have been redefined to optimize support for standard protocols such as RECIST and PERCIST. In addition, powerful imaging solutions have been introduced to support better collaborative working, in particular in the context of a rich web-based viewer for referring physicians and a robust solution for presentation of images at multidisciplinary meetings such as tumor board.

Mirada Medical, Fusion XD and Casemeeting are all trademarks of Mirada Medical Ltd.

For more information, visit www.mirada-medical.com

Mirada Medical ECCO release: http://hugin.info/143183/R/1548058/475700.pdf